

厚生労働行政推進調査事業費補助金（肝炎等克服政策研究事業）
分担研究報告書

肝がん・重度肝硬変の医療水準と患者の QOL 向上等に資する研究

工藤 正俊 近畿大学医学部 消化器内科 主任教授

データ収集プラットフォーム整備

A 研究目的

肝癌に対する免疫療法と局所治療の組み合わせの効果と安全性を検証する事。特に各国の研究状況と成績における実態調査を行う事。

B 研究方法

肝癌に対する各種国際学会に出席し発表を行うとともに、海外のデータについても日本との成績と比較検討する。

C 研究結果

日本の肝癌における複合免疫療法と局所治療の組み合わせが海外とはアプローチ方法が異なり、最も優れている事が判明した。

D 考察

今後日本において、肝癌の治療を効率的に進めるには複合免疫療法の経済的サポートと共に局所治療と組み合わせる事が重要と考えられた。

E 結論

日本の肝癌の治療、特に複合免疫療法による治療成績は海外より優れていると考えられた。これについては、日本独自の局所治療との組み合わせは極めて重要であると考えられた。

F 健康危険情報

なし

G 研究発表

1. 論文発表

1. Ikeda M, Yamashita T, Ogasawara S, Kudo M, Inaba Y, Morimoto M, Tsuchiya K, Shimizu S, Kojima Y, Hiraoka A, Nouse K, Aikata H, Numata K, Sato T, Okusaka T, Furuse J: Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. Liver Cancer 13:193-202, 2024.
2. Kudo M: Objective response to systemic therapy is a strong predictor of overall survival in patients with unresectable hepatocellular carcinoma. Liver Cancer 13:1-5, 2024. <https://doi.org/10.1159/000535516>
3. Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N: Incidence of hyper progressive disease in combination immunotherapy and anti-PD-1/PD-L1 monotherapy for unresectable hepatocellular carcinoma. Liver Cancer 13:56-69, 2024. <https://doi.org/10.1159/000531024>
4. Kudo M, Ueshima K, Saeki I, Ishikawa T,

- Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y: A Phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable Intermediate-stage hepatocellular carcinoma: TACTICS-L trial. *Liver Cancer* 13:99-112,2024.
<https://doi.org/10.1159/000531377>
5. Kariyama K, Nouse K, Hiraoka A, Toyoda H, Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kudo M, Kumada T: Treatment options for solitary hepatocellular carcinoma ≤ 5 cm: Surgery vs ablation: A multicenter retrospective study. *J Liver Cancer* 24:71-80, 2024.
 6. Kudo M: Urgent global need for PIVKA-II and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma. *Liver Cancer* 13:113-118, 2024.
 7. Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T: Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study. *Hepatol Res* 54:382-391, 2024.
 8. Kudo M: Immune checkpoint inhibitors plus anti-VEGF/Tyrosine kinase inhibitors combined with TACE (Triple therapy) in unresectable hepatocellular carcinoma. *Liver Cancer* 13:227-234, 2024.
 9. Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Tsurusaki M, Nakai T, Sakamoto M, Nishio K, Kudo M: Two distinct characteristics of immune microenvironment in human hepatocellular carcinoma with Wnt/ β -catenin mutations. *Liver Cancer* 13:285-305, 2024. DOI:10.1159/000533818.
 10. Kudo M: A changing role of transarterial chemoembolization in the era of immune checkpoint inhibitor plus anti-VEGF/TKI plus transarterial chemoembolization: From total embolization to partial embolization (Immune Boost Transarterial Chemoembolization). *Liver Cancer* 13:335-343, 2024.
 11. Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, on behalf of the Real-life Practice Experts for HCC URELPEC) Study Group: Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not

- meet the inclusion criteria for the phase 3 IMbrave150 trial. *Aliment Pharm Ther* 60:233-245, 2024.
12. Kudo M: Nivolumab plus Ipilimumab: A novel first-line combination immunotherapy for unresectable hepatocellular carcinoma. *Liver Cancer* 13:459-467, 2024.
 13. Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T, on behalf of the Real-life Practice Experts for HCC Study Group and HCC 48 Group: Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients. *Aliment Pharm Ther* 60:1361-1373, 2024.
 14. Kudo M: Challenges in adjuvant immunotherapy after resection or ablation for hepatocellular carcinoma at high-risk of recurrence. *Liver Cancer* 13:573-578, 2024
 15. Kudo M, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M: Reply to the Letter regarding "Impact of bevacizumab being skipped due to adverse events of special interest for bevacizumab in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: An exploratory analysis of the Phase III IMbrave150 study. *Liver Cancer* 13:671-673, 2024.
 16. Kudo M: Systemic therapy combined with locoregional therapy in intermediate-stage hepatocellular carcinoma. *Intervent Radiol*, 2024.
<https://doi.org/10.22575/interventionalradiology.2023-0035>

2.学会発表

1. Kudo M, Cheng AL, Merle P, Ryoo BY, Decaens T, Cicin I, Dajani O, Al-Rajabi R, Péron JM, Chan SL, Knox J, Daniele B, Suttner L, Webber AL, Pena C, Cristescu R, Chen C, Hatogai K, Siegel AB, Finn RS: Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): exploratory analyses from KEYNOTE-240. ASCO 2024, McCormick Place, Chicago, USA, May 31-June 4, 2024.
2. Kudo M, Chan SL, Sangro B, Erinjeri JP, Qin S, Ren Z, Arai Y, Breder VV, Lin SM, Peron JM, Nguyen TQ, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Morgan C, Parsons K, Xynos I, Lencioni R: Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. ASCO Breakthrough 2024, Pacifico Yokohama, Japan, August 8-10, 2024.
3. Kudo M, Lencioni R, Erinjeri JP, Chan SL, Qin S, Ren Z, Arai Y, Heo J, Breder VV, Bouattour M, Dayyani F, Yoon J, Chiu C, Suttichaimongkol T, Decaens T, Morgan C, Ali S, Balaji K, Sangro B: Impact of baseline tumour burden on outcomes in EMERALD-1:

- A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC). (ESMO 2024), Barcelona, Spain, September 13-17, 2024.
4. Kudo M, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Nakagawa Y, Takahashi H, Ikeda M: Depth of response (DpR) and duration of response (DoR) are associated with overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Exploratory analyses of IMbrave150. 18th ILCA Annual Conference (ILCA 2024), Toronto, Canada, October 17-19, 2024.
 5. 西田直生志, 工藤正俊: AI 開発用超音波画像ビッグデータベースとオンライン性能評価試験 システムの構築. JDDW 2024 (第 66 回日本消化器病学会大会, 第 108 回日本消化器内視鏡学会総会, 第 28 回日本肝臓学会大会), 令和 6 年 10 月 31 日-11 月 3 日, 神戸コンベンションセンター, 兵庫.
 6. Kudo M, Yau T, Decaens T, Sangro B, Qin S, Da Fonseca L, Karachiwala H, Park JW, Gane E, Pinter M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Hu N, Jesus M, Exposito J, Stromko C, Galle PR: Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2025), San Francisco, USA, January 23-25, 2025.
 7. Ikeda M, Terashima T, Yamashita T, Okusaka T, Imaoka H, Kawaoka T, Kobayashi S, Ogasawara S, Hiraoka A, Nakano M, Nagashima F, Sugimoto R, Moriguchi M, Inaba Y, Shinoda S, Ueno M, Kato N, Kudo M, Furuse J, Nagano H: A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh class B cirrhosis: CHALLENGE trial final results. ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2025), San Francisco, USA, January 23-25, 2025.
 8. Kudo M, Rimassa L, Chan S, Sangro B, Lau G, Breder V, Varela M, Crysler O, Bouattour M, Dao TV Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Dayyani F, Paskow M, Makowsky M, Ran D, Negro A, Abou-Alfa G: Five-year overall survival and overall survival by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. SIO 2025 Annual Meeting, Paris, France, January 30-February 3, 2025.
- H 知的財産権の出願・登録状況 (予定を含む)
1. 特許取得: なし
 2. 実用新案登録: なし
 3. その他: なし